Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > You know why Musgy can't tell me to screw off?

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Sep 20, 2021 9:05am

126 Views

Post# 33885816

RE:RE:You know why Musgy can't tell me to screw off?

EfTOates28 wrote:
how many shares do you have?

Oates, In case you're asking me, my numbers have been quite transparent in our discussions here from 2017 to 2020. There's no point rehashing that.

I've added another 40K+ shares this year. Mostly around $1.10 ... but I was also picking up shares before and after the last spike (Feb 2021) in the $3-$4 range.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale